These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34350590)

  • 1. Everything old is new again.
    Freitag FG
    Headache; 2021 Sep; 61(8):1286. PubMed ID: 34350590
    [No Abstract]   [Full Text] [Related]  

  • 2. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
    Tfelt-Hansen P; Loder E
    Headache; 2019 Jan; 59(1):113-117. PubMed ID: 30451300
    [No Abstract]   [Full Text] [Related]  

  • 4. A new dihydroergotamine nasal spray (Trudhesa) for migraine.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):204-207. PubMed ID: 35100240
    [No Abstract]   [Full Text] [Related]  

  • 5. Rimegepant: acute treatment for migraine headaches.
    Peters GL; Hennessey EK
    Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-927711 for the acute treatment of migraine.
    Bigal ME
    Cephalalgia; 2014 Feb; 34(2):90-2. PubMed ID: 23943638
    [No Abstract]   [Full Text] [Related]  

  • 8. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
    DeFalco AP; Lazim R; Cope NE
    Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Croop R; Lipton RB; Kudrow D; Stock DA; Kamen L; Conway CM; Stock EG; Coric V; Goadsby PJ
    Lancet; 2021 Jan; 397(10268):51-60. PubMed ID: 33338437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine.
    Stead M; Josephs KA
    Headache; 2005 Apr; 45(4):378-80. PubMed ID: 15836577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimegepant (Nurtec ODT) for Acute Treatment of Migraine.
    JAMA; 2020 Sep; 324(9):890-891. PubMed ID: 32870296
    [No Abstract]   [Full Text] [Related]  

  • 13. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies.
    Tfelt-Hansen P
    Cephalalgia; 2000 Mar; 20(2):137. PubMed ID: 10961773
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of the acute migraine attack].
    Titus F
    Rev Neurol; 1995; 23 Suppl 2():S203-7. PubMed ID: 7497289
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine.
    Blumenfeld AM; Edvinsson L; Jakate A; Banerjee P
    J Fam Pract; 2020; 69(1 Suppl):S8-S12. PubMed ID: 32053714
    [No Abstract]   [Full Text] [Related]  

  • 17. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 18. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C; Ortega-Valín F; Valero M; Muñoz R; Pascual J
    Neurologia; 1999; 14(6):315-8. PubMed ID: 10439626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.